A detailed history of Credit Suisse Ag transactions in Arvinas, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 262,224 shares of ARVN stock, worth $5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
262,224
Previous 142,108 84.52%
Holding current value
$5 Million
Previous $5.85 Million 85.06%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$36.38 - $52.31 $4.37 Million - $6.28 Million
120,116 Added 84.52%
262,224 $10.8 Million
Q4 2023

Feb 08, 2024

BUY
$14.19 - $42.33 $1.23 Million - $3.68 Million
86,845 Added 157.15%
142,108 $5.85 Million
Q3 2023

Nov 13, 2023

SELL
$19.64 - $28.21 $7,757 - $11,142
-395 Reduced 0.71%
55,263 $1.09 Million
Q2 2023

Aug 11, 2023

BUY
$21.73 - $31.43 $71,296 - $103,121
3,281 Added 6.26%
55,658 $1.38 Million
Q1 2023

May 10, 2023

BUY
$26.15 - $37.26 $83,183 - $118,524
3,181 Added 6.47%
52,377 $1.43 Million
Q4 2022

Feb 13, 2023

BUY
$32.47 - $57.24 $354,767 - $625,404
10,926 Added 28.55%
49,196 $1.68 Million
Q3 2022

Nov 10, 2022

BUY
$41.87 - $57.99 $87,592 - $121,315
2,092 Added 5.78%
38,270 $1.7 Million
Q2 2022

Aug 12, 2022

BUY
$36.01 - $74.24 $66,258 - $136,601
1,840 Added 5.36%
36,178 $1.52 Million
Q1 2022

May 16, 2022

BUY
$60.27 - $81.57 $345,949 - $468,211
5,740 Added 20.07%
34,338 $2.31 Million
Q4 2021

Feb 14, 2022

SELL
$65.85 - $96.21 $150,796 - $220,320
-2,290 Reduced 7.41%
28,598 $2.35 Million
Q3 2021

Nov 12, 2021

BUY
$73.2 - $107.87 $14,127 - $20,818
193 Added 0.63%
30,888 $2.54 Million
Q2 2021

Aug 16, 2021

BUY
$60.45 - $84.26 $348,736 - $486,095
5,769 Added 23.14%
30,695 $2.36 Million
Q1 2021

May 14, 2021

SELL
$58.19 - $91.37 $517,600 - $812,736
-8,895 Reduced 26.3%
24,926 $1.65 Million
Q4 2020

Feb 12, 2021

BUY
$20.19 - $84.93 $343,573 - $1.45 Million
17,017 Added 101.27%
33,821 $2.87 Million
Q3 2020

Nov 13, 2020

SELL
$22.99 - $36.34 $29,450 - $46,551
-1,281 Reduced 7.08%
16,804 $395,000
Q2 2020

Aug 12, 2020

BUY
$29.88 - $56.74 $205,813 - $390,825
6,888 Added 61.52%
18,085 $606,000
Q1 2020

May 13, 2020

SELL
$33.0 - $54.5 $508,332 - $839,518
-15,404 Reduced 57.91%
11,197 $451,000
Q4 2019

Feb 12, 2020

BUY
$15.39 - $44.38 $210,273 - $606,363
13,663 Added 105.6%
26,601 $1.09 Million
Q3 2019

Nov 12, 2019

BUY
$21.55 - $27.61 $278,813 - $357,218
12,938 New
12,938 $278,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.